{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T09:11:20Z","timestamp":1648717880969},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,12,3]],"date-time":"2013-12-03T00:00:00Z","timestamp":1386028800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s00198-013-2589-x","type":"journal-article","created":{"date-parts":[[2013,12,2]],"date-time":"2013-12-02T17:08:47Z","timestamp":1386004127000},"page":"1415-1417","source":"Crossref","is-referenced-by-count":0,"title":["Aseptic necrosis at multiple localisations in a lupus patient with lymphoma"],"prefix":"10.1007","volume":"25","author":[{"given":"A.","family":"Bazso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Bazso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Szodoray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Poor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,3]]},"reference":[{"key":"2589_CR1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.autrev.2010.06.007","volume":"9","author":"C Powell","year":"2010","unstructured":"Powell C, Chang C, Naguwa SM et al (2010) Steroid induced osteonecrosis: an analysis of steroid dosing risk. Autoimmune Rev 9:721\u2013743","journal-title":"Autoimmune Rev."},{"key":"2589_CR2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.autrev.2012.12.002","volume":"12","author":"LP Seguro","year":"2013","unstructured":"Seguro LP, Rosario C, Shoenfeld Y (2013) Long-term complications of past glucocorticoid use. Autoimmune Rev 12:629\u2013632","journal-title":"Autoimmune Rev."},{"key":"2589_CR3","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O","volume":"43","author":"A Zonana Nacach","year":"2000","unstructured":"Zonana Nacach A, Barr SG, Magder LS et al (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43:1801\u20131808","journal-title":"Arthritis Rheum"},{"key":"2589_CR4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/sarh.2002.33724b","volume":"32","author":"Y Assouline-Dayan","year":"2002","unstructured":"Assouline-Dayan Y, Chang C, Greenspa A et al (2002) Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32:94\u2013124","journal-title":"Semin Arthritis Rheum"},{"key":"2589_CR5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.7326\/0003-4819-112-9-682","volume":"112","author":"PE Love","year":"1990","unstructured":"Love PE, Santoro SA (1990) Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythaematosus (SLE) and in non-SLE disorders; prevalence and clinical significance. Ann Intern Med 112:682\u2013698","journal-title":"Ann Intern Med"},{"key":"2589_CR6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/RHU.0b013e31819dbd20","volume":"15","author":"JC Rueda","year":"2009","unstructured":"Rueda JC, Duque MA, Mantilla RD et al (2009) Osteonecrosis and antiphospholipid syndrome. J Clin Rheumatol 15:130\u2013132","journal-title":"J Clin Rheumatol"},{"key":"2589_CR7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/01.rhu.0000135559.95451.b2","volume":"10","author":"A Zonana-Nacach","year":"2004","unstructured":"Zonana-Nacach A, Jim\u00e9nez-Balderas FJ (2004) Avascular necrosis of bone associated with primary antiphospholipid syndrome: case report and literature review. J Clin Rheumatol 10:214\u2013217","journal-title":"J Clin Rheumatol"},{"key":"2589_CR8","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/rheumatology\/37.4.448","volume":"37","author":"FA Houssiau","year":"1998","unstructured":"Houssiau FA, N\u2019Zeusseu Toukap A, Depresseux G et al (1998) Magnetic resonance imaging-detected avascular osteonecrosis in systemic lupus erythematosus: lack of correlation with antiphospholipid antibodies. Br J Rheumatol 37:448\u2013453","journal-title":"Br J Rheumatol"},{"key":"2589_CR9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/096120339400300108","volume":"3","author":"S Migliaresi","year":"1994","unstructured":"Migliaresi S, Picillo U, Ambrosone L et al (1994) Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies. Lupus 3:37\u201341","journal-title":"Lupus"},{"key":"2589_CR10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1422.008","volume":"1108","author":"T Tarr","year":"2007","unstructured":"Tarr T, Gyorfy B, Szekanecz E, Bhattoa HP, Zeher M, Szegedi G, Kiss E (2007) Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus. Results from a single centre. Ann NY Acad Sci 1108:76\u201382","journal-title":"Ann NY Acad Sci."},{"issue":"4","key":"2589_CR11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.autrev.2009.07.004","volume":"9","author":"E Kiss","year":"2010","unstructured":"Kiss E, Kovacs L, Szodoray P (2010) Malignancies in systemic lupus erythematosus. Autoimmun Rev 9(4):195\u2013199","journal-title":"Autoimmun Rev"},{"key":"2589_CR12","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1634\/theoncologist.2009-0003","volume":"14","author":"O Sezer","year":"2009","unstructured":"Sezer O (2009) Myeloma bone disease: recent advances in biology, diagnosis, and treatment. The Oncoogist 14:276\u2013283","journal-title":"The Oncoogist"},{"key":"2589_CR13","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","volume":"98","author":"N Giuliani","year":"2003","unstructured":"Giuliani N, Bataille R, Mancini C et al (2003) Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527\u20133533","journal-title":"Blood"},{"key":"2589_CR14","first-page":"1436","volume":"9","author":"U Heider","year":"2003","unstructured":"Heider U, Langelotz C, Jakob C et al (2003) Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 9:1436\u20131440","journal-title":"Clin Cancer Res"},{"key":"2589_CR15","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","volume":"100","author":"M Abe","year":"2002","unstructured":"Abe M, Hiura K, Wilde J et al (2002) Role of macrophage inflammatory protein (MIP)-1\u03b1 and MIP-1\u03b2 in the development of osteolytic lesions in multiple myeloma. Blood 100:2195\u20132202","journal-title":"Blood"},{"key":"2589_CR16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0961203306075793","volume":"16","author":"LY Sun","year":"2007","unstructured":"Sun LY, Zhang HY, Feng XB et al (2007) Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 16:121\u2013128","journal-title":"Lupus"},{"key":"2589_CR17","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-04-1687","volume":"65","author":"AC Zannettino","year":"2005","unstructured":"Zannettino AC, Farrigia AN, Kortesidis A et al (2005) Elevated serum levels of stromal-derived factor-1\u03b1 are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 65:1700\u20131709","journal-title":"Cancer Res"},{"key":"2589_CR18","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3109\/1354750X.2012.728623","volume":"17","author":"G Toldi","year":"2012","unstructured":"Toldi G, Szalay B, Bek\u0151 G, Bocskai M et al (2012) Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus. Biomarkers 17:758\u2013763","journal-title":"Biomarkers"},{"key":"2589_CR19","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1055\/s-2004-832341","volume":"216","author":"B Bernbeck","year":"2004","unstructured":"Bernbeck B, Christaras A, Krauth K et al (2004) Bone marrow oedema and aseptic osteonecrosis in children and adolescents with acute lymphoblastic leukaemia or non-Hodgkin-lymphoma treated with hyperbaric-oxygen-therapy (HBO): an approach to cure?\u2014BME\/AON and hyperbaric oxygen therapy as a treatment modality. Klin Padiatr 216:370\u2013378","journal-title":"Klin Padiatr"},{"key":"2589_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0609.2008.01164.x","volume":"82","author":"U Heider","year":"2009","unstructured":"Heider U, Kaiser M, Mieth M et al (2009) Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 82:31\u201338","journal-title":"Eur J Haematol"},{"key":"2589_CR21","first-page":"424","volume":"73","author":"Alcocer-Varela","year":"1988","unstructured":"Alcocer-Varela, Vidaller A, Llorente L (1988) Presence of an IL-3-producing suppressor T cell resistant to cyclosporin A in the peripheral blood of patients with systemic lupus erythematosus. Clin Exp Immunol 73:424\u2013429","journal-title":"Clin Exp Immunol"},{"key":"2589_CR22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/BOR.0b013e32835fd682","volume":"25","author":"Z Paz","year":"2013","unstructured":"Paz Z, Tsokos GC (2013) New therapeutics in systemic lupus erythematosus. Curr Opin Rheumatol 25:297\u2013303","journal-title":"Curr Opin Rheumatol"},{"key":"2589_CR23","first-page":"302","volume":"2013","author":"HC Lee","year":"2013","unstructured":"Lee HC, Shah JJ, Orlowski RZ (2013) Novel approaches to treatment of double-refractory multiple myeloma. Am Soc Clin Oncol Educ Book 2013:302\u2013306","journal-title":"Am Soc Clin Oncol Educ Book."}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-013-2589-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-013-2589-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-013-2589-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T05:41:18Z","timestamp":1597124478000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-013-2589-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,3]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["2589"],"URL":"https:\/\/doi.org\/10.1007\/s00198-013-2589-x","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,3]]}}}